Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;18(11):2252-2261.
doi: 10.1002/alz.12576. Epub 2022 Feb 1.

Quantifying longitudinal cognitive resilience to Alzheimer's disease and other neuropathologies

Affiliations

Quantifying longitudinal cognitive resilience to Alzheimer's disease and other neuropathologies

Maude Wagner et al. Alzheimers Dement. 2022 Nov.

Abstract

Introduction: Cognitive resilience (CR) has been defined as the continuum of better (or worse) than expected cognition, given the degree of neuropathology. To quantify this concept, existing approaches focus on either cognitive level at a single time point or slopes of cognitive decline.

Methods: In a prospective study of 1215 participants, we created a continuous measure of CR defined as the mean of differences between estimated person-specific and marginal cognitive levels over time, after accounting for neuropathologies.

Results: Neuroticism and depressive symptoms were associated with all CR measures (P-values < .012); as expected, cognitive activity and education were only associated with the cognitive-level approaches (P-values < .0002). However, compared with the existing CR measures focusing on a single measure or slopes of cognition, our new measure yielded stronger relations with risk factors.

Discussion: Defining CR based on the longitudinal differences between person-specific and marginal cognitive levels is a novel and complementary way to quantify CR.

Keywords: Alzheimer's dementia; cognitive resilience; longitudinal study; mixed-effects model; neuropathology; neuropsychological tests.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors have no conflicts to declare.

Figures

Figure 1.
Figure 1.
Graphs illustrating the three strategies used to quantify cognitive resilience (CR) at the individual level. The graphs each represent an individual with 5 repeated observations of global cognition collected over 12 years preceding death. The CRLast_level (panel A) is computed as the standardized difference between the observed and the estimated levels of global cognition (i.e., standardized residuals) proximate to death from a linear regression model accounting for demographics and neuropathologic indices. The CRslope (panel B) is defined as the person-specific deviation from the rate of cognitive decline expected at the population level (i.e., random slope), estimated in a latent process mixed-effects (LPM) model assuming linearity and adjusted for demographic and neuropathologic indices. Finally, CRLevel¯(panel C) corresponds to the mean of the differences between the person-specific and the marginal estimations of global cognition at each measurement time estimated in a LPM model allowing non-linearity and adjusted for demographic and neuropathologic indices. For CRslope and CRLevel¯ (panels C–D), marginal trajectories represent the expected shape of cognition among individuals sharing similar profile of covariates (demographics and pathologic indices) as the theoretical individual.
Figure 2.
Figure 2.
Illustrative examples of two participants with varying z-scores of cognitive resilience (CR) and different estimated trajectories of cognition before death: Religious Orders Study and Rush Memory and Aging Project.
Figure 3.
Figure 3.
Distributions of CRLast_level, CRslope, and CRLevel¯, and scatterplots of the relationship between CRLast_level and CRLevel¯ (panel A), and CRslope and CRLevel¯ (panel B); Religious Orders Study and Rush Memory and Aging Project (n=1,215).

Similar articles

Cited by

References

    1. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58(4):376–388. doi:10.1097/00005072-199904000-00008 - DOI - PubMed
    1. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. “Preclinical” AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000;55(3):370–376. doi:10.1212/wnl.55.3.370 - DOI - PubMed
    1. Iacono D, Markesbery WR, Gross M, et al. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology. 2009;73(9):665–673. doi:10.1212/WNL.0b013e3181b01077 - DOI - PMC - PubMed
    1. Ewbank DC, Arnold SE. Cool with plaques and tangles. N Engl J Med. 2009;360(22):2357–2359. doi:10.1056/NEJMe0901965 - DOI - PubMed
    1. Price JL, McKeel DW, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026–1036. doi:10.1016/j.neurobiolaging.2009.04.002 - DOI - PMC - PubMed

Publication types